Zervimesine (CT1812) - (SHIMMER)

May 21, 2026: Cognition Therapeutics, Inc. (NASDAQ: CGTX) reported it held a planned meeting with the FDA on May 20, 2026 to review Phase 2 results from zervimesine (CT1812) in the COG1201 “SHIMMER” study in dementia with Lewy bodies (DLB) and to discuss the design and endpoints for a registrational (late-stage) study in DLB patients with psychosis. The company said the discussion was productive and that it believes there is a path forward to advance zervimesine into a registrational program for DLB psychosis; it expects to receive FDA formal meeting minutes in June.

Additional program context: zervimesine is being studied in the Phase 2 START study (NCT05531656) in mild cognitive impairment (MCI) and early Alzheimer’s disease; Phase 2 studies have also concluded in mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The USAN Council adopted “zervimesine” as the United States Adopted Name for CT1812.